JUVELOOK

Product Overview

JUVELOOK is a Korean injectable collagen biostimulator and tissue-repair product developed by VAIM Co., Ltd. The product family combines poly-D,L-lactic acid (PDLLA) with hyaluronic acid (HA) in a biodegradable formulation designed for temporary improvement of facial wrinkles through physical tissue augmentation. The range includes JUVELOOK i 30 mg, JUVELOOK 50 mg, and JUVELOOK Volume 200 mg, offering different compositions and formulation characteristics for distinct facial aesthetic requirements.

JUVELOOK products feature VAIM's proprietary porous, reticular PDLLA particle technology. The formulations combine the physical tissue-supporting properties of hyaluronic acid with the collagen-stimulating characteristics of biodegradable PDLLA particles.

This product page brings together three JUVELOOK formulations for professional buyers comparing PDLLA content, HA composition, product characteristics, and intended applications. Each formulation is intended for administration by appropriately qualified healthcare professionals, subject to its approved indications and applicable medical device regulations.

Key Features

• Hybrid PDLLA + HA Formulation: Combines biodegradable poly-D,L-lactic acid with hyaluronic acid to provide physical tissue support and a material platform associated with collagen stimulation.
• Three Distinct Formulations: JUVELOOK i 30 mg, JUVELOOK 50 mg, and JUVELOOK Volume 200 mg contain different amounts of PDLLA and HA for different facial correction requirements.
• Porous Reticular PDLLA Particles: VAIM uses proprietary technology to manufacture PDLLA particles with a porous, interconnected structural morphology.
• Biodegradable Polymer: PDLLA undergoes gradual hydrolytic degradation, while its interaction with surrounding tissue is associated with extracellular matrix remodeling and collagen formation.
• South Korean Medical Device: Developed by VAIM Co., Ltd., with the JUVELOOK product family classified in South Korea as tissue-repair medical devices.

Composition & Specifications

JUVELOOK formulations contain poly-D,L-lactic acid (PDLLA) and hyaluronic acid (HA). PDLLA is a biodegradable synthetic polymer, while HA is a naturally occurring glycosaminoglycan known for its water-binding properties.

The three formulations share the same principal ingredient categories but differ in total material content and intended product positioning. The stated milligram quantities refer to the dry material content per vial, not the concentration of a prepared injectable suspension.

Understanding the PDLLA + HA Composition

All three formulations contain PDLLA and HA in an 85:15 ratio by declared material weight. However, the total content differs significantly between products. JUVELOOK i contains 30 mg of combined material, standard JUVELOOK contains 50 mg, and JUVELOOK Volume contains 200 mg.

These differences are important for product identification, but total material content alone does not establish equivalent treatment performance or clinical interchangeability. Particle characteristics, preparation requirements, product-specific labeling, and intended applications must also be considered.

How JUVELOOK PDLLA + HA Technology Works

JUVELOOK combines two materials with complementary physical and biological characteristics: biodegradable poly-D,L-lactic acid and hyaluronic acid.

PDLLA and Collagen Stimulation

Poly-D,L-lactic acid is a biodegradable polymer used in selected injectable tissue-repair and collagen-stimulating medical devices. Following implantation, PDLLA particles interact with surrounding tissue through a localized foreign-body response involving immune cells and tissue-remodeling processes.

Experimental research involving PDLLA-based materials has demonstrated changes in extracellular matrix activity, fibroblast-related processes, and collagen production. These biological responses provide a scientific basis for the use of PDLLA as a collagen biostimulator.

The development and magnitude of collagen-related changes depend on formulation characteristics, tissue response, and individual biological factors. Findings from ingredient research or experimental models should not be interpreted as guaranteed clinical outcomes for every JUVELOOK formulation.

Hyaluronic Acid and Physical Tissue Support

Hyaluronic acid is a hydrophilic polysaccharide naturally present in the extracellular matrix. Its capacity to bind water contributes to tissue hydration and the viscoelastic properties of biological tissues.

Within JUVELOOK formulations, HA forms part of the combined tissue-repair material. Its presence contributes to the formulation's physical characteristics, while PDLLA provides the biodegradable polymer component associated with longer-term tissue remodeling.

VAIM's Porous Reticular Particle Technology

VAIM describes the PDLLA particles used in JUVELOOK as having a porous reticular structure manufactured through its proprietary patented technology.

This structural design distinguishes the JUVELOOK material platform from conventional descriptions of solid polymer microspheres. However, particle morphology alone does not establish superior safety, clinical effectiveness, or the absence of nodules and other complications.

Available JUVELOOK Variants

The JUVELOOK range includes three formulations with different total material contents and product positioning. JUVELOOK i is associated with delicate periorbital correction, standard JUVELOOK with facial skin-quality and wrinkle-related applications, and JUVELOOK Volume with volume-oriented facial correction.

JUVELOOK i — 30 mg

JUVELOOK i is a specialized PDLLA + HA formulation containing 25.5 mg of poly-D,L-lactic acid and 4.5 mg of hyaluronic acid, providing a total declared material content of 30 mg per vial.

JUVELOOK i is positioned within the manufacturer's product range for delicate facial correction, particularly concerns involving the periorbital area. The thin skin and complex anatomical structures surrounding the eyes require careful professional assessment and product-specific clinical considerations.

Although JUVELOOK i contains the same principal material categories as the other formulations, its lower total content and specialized positioning distinguish it from standard JUVELOOK and JUVELOOK Volume.

JUVELOOK 50 mg — Original Formulation

JUVELOOK 50 mg is the standard formulation in the JUVELOOK product family. Each vial contains 42.5 mg of PDLLA and 7.5 mg of HA, totaling 50 mg of combined material.

This formulation is associated with facial wrinkle correction and skin-quality applications. Its combination of biodegradable PDLLA particles and HA provides a hybrid material platform for physical tissue restoration and collagen-related remodeling.

The standard JUVELOOK formulation differs from JUVELOOK Volume in total material content and product characteristics. It is not simply a smaller quantity of the same finished formulation.

JUVELOOK Volume 200 mg — Volume-Oriented Formulation

JUVELOOK Volume 200 mg contains 170 mg of poly-D,L-lactic acid and 30 mg of hyaluronic acid per vial, providing a total declared material content of 200 mg.

This formulation is positioned for facial volume correction and contour-related applications. Its larger total polymer content and formulation-specific particle characteristics distinguish it from JUVELOOK i and the standard 50 mg product.

The 200 mg PDLLA + HA formulation is marketed under the JUVELOOK Volume name in South Korea. In certain international markets, a related 200 mg formulation is marketed under the LENISNA name. Product names, registrations, and labeling must be verified for the specific market and supplied SKU.

The three products are distinct formulations and should not be treated as clinically interchangeable. Their intended applications and permitted use depend on the individual product's approved labeling and applicable national regulations.

Packaging & Product Presentation

JUVELOOK products are supplied as dry material in vials rather than pre-filled hyaluronic acid gel syringes. The declared milligram strength identifies the combined PDLLA and HA material content in each vial.

The material must be prepared according to the manufacturer's product-specific instructions before professional administration. Preparation requirements, supplied accessories, and commercial box configurations may differ between formulations and destination markets.

The declared milligram content is not the final injectable volume. Verify the exact vial count, packaging configuration, batch number, expiration date, and applicable instructions for use before ordering or using a product.

Storage & Handling

JUVELOOK products must be stored and handled according to the original manufacturer labeling and instructions for use supplied with the specific formulation. Storage requirements should not be assumed to be identical across all market versions.

• Original Packaging: Keep the product in its original manufacturer packaging until required for professional use.
• Environmental Conditions: Follow the temperature, humidity, and light-exposure restrictions stated on the applicable product label.
• Product Integrity: Do not use a vial if its packaging, seal, or sterile barrier has been compromised.
• Single-Use Presentation: Follow the manufacturer's single-use and disposal requirements. Do not reuse or resterilize the product.
• Traceability: Confirm the product name, formulation strength, lot number, expiration date, and market-specific labeling.

Exact storage temperatures and post-preparation handling requirements must be confirmed from the instructions supplied with each product. No universal temperature range or preparation protocol is implied for the entire JUVELOOK family.

Safety & Professional Use

JUVELOOK i, JUVELOOK 50 mg, and JUVELOOK Volume 200 mg are injectable medical products intended for appropriately qualified healthcare professionals. Their use requires knowledge of facial anatomy, product-specific indications, contraindications, and potential complications.

Reactions associated with injectable tissue-repair materials may include localized swelling, redness, tenderness, bruising, inflammation, and discomfort. Potential complications include infection, persistent nodules, granulomatous reactions, asymmetry, and other inflammatory responses.

As with other facial injectable products, accidental intravascular administration can lead to vascular compromise and serious tissue injury. Injection-related vascular events may also result in visual impairment or other severe complications.

The biodegradable nature of PDLLA does not eliminate the possibility of delayed adverse reactions. Product-specific safety information, contraindications, and precautions must be reviewed before clinical use.

South Korean medical device classification does not establish authorization in other countries. Buyers and healthcare professionals should verify the regulatory status, permitted indications, and professional-use requirements applicable to their jurisdiction.

This description is intended for professional product identification and comparison. It does not constitute medical advice, establish patient suitability, or replace official instructions for use.

Frequently Asked Questions